High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization
Baogen Zhang,1,* Biqing Huang,2,* Fan Yang,3,* Jiandong Yang,1 Man Kong,1 Jing Wang,1 Yaoxian Xiang,1 Kangjie Wang,1 Ruchen Peng,4 Kun Yang,4 Chao An,5 Dong Yan1 1Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2024-03-01
|
| Series: | Journal of Hepatocellular Carcinoma |
| Subjects: | |
| Online Access: | https://www.dovepress.com/high-risk-hepatocellular-carcinoma-hepatic-arterial-infusion-chemother-peer-reviewed-fulltext-article-JHC |
| _version_ | 1797243529643163648 |
|---|---|
| author | Zhang B Huang B Yang F Yang J Kong M Wang J Xiang Y Wang K Peng R Yang K An C Yan D |
| author_facet | Zhang B Huang B Yang F Yang J Kong M Wang J Xiang Y Wang K Peng R Yang K An C Yan D |
| author_sort | Zhang B |
| collection | DOAJ |
| description | Baogen Zhang,1,* Biqing Huang,2,* Fan Yang,3,* Jiandong Yang,1 Man Kong,1 Jing Wang,1 Yaoxian Xiang,1 Kangjie Wang,1 Ruchen Peng,4 Kun Yang,4 Chao An,5 Dong Yan1 1Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s Republic of China; 2Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People’s Republic of China; 3Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People’s Republic of China; 4Department of Medical Imaging, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s Republic of China; 5Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dong Yan, Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s Republic of China, Tel/Fax +86-10-69543901, Email dongyan@mail.ccmu.edu.cn Chao An, Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China, Tel/Fax +86-20-87343272, Email anchao-1983@163.comObjective: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) for the treatment of high-risk hepatocellular carcinoma (hHCC) patients.Methods: Between January 2014 and August 2022, a total of 1765 consecutive patients with hHCC who underwent initial intra-arterial therapies were reviewed and divided into a TACE group (n, 507) and a HAIC group (n, 426). The study used propensity score matching (PSM) to reduce selectivity bias. Overall survival (OS) and progression-free survival (PFS) were compared using Kaplan‒Meier curves with the Log rank test. The objective response rate (ORR), conversion surgery rate (CSR) adverse event (AE) comparison and subgroup analysis were performed between the two groups.Results: After PSM 1:1, 444 patients were divided into two groups. The patients with hHCC who received HAIC had higher median PFS (6.1 vs 3.3 months, P < 0.001) and OS (10.3 vs 8.2 months, P=0.303) than TACE. Higher ORR (24.8% vs 11.7%) and CSR (15.5% vs 8.9%) were found in the HAIC group than in the TACE group (both P < 0.05). The incidence of grade 3/4 AE was 23.9% and 8.1% in the TACE and HAIC groups, respectively. The subgroup analysis suggest that HAIC appeared to particularly benefit patients with tumor diameter of more than 10 centimeters (hazard ratio [HR], 0.6; 95% CI, 0.47– 0.77; p, 0.00) and PVTT Vp4 (HR, 0.56; 95% CI, 0.39– 0.8; P, 0.01) for PFS outperforming TACE.Conclusion: HAIC can provide better disease control for hHCC than cTACE, with a comparable long-term OS and safety.Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery infusion chemotherapy, high risk |
| first_indexed | 2024-04-24T18:56:34Z |
| format | Article |
| id | doaj.art-b64a6531a0ee4c53bb0c2088979ec2e2 |
| institution | Directory Open Access Journal |
| issn | 2253-5969 |
| language | English |
| last_indexed | 2024-04-24T18:56:34Z |
| publishDate | 2024-03-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Hepatocellular Carcinoma |
| spelling | doaj.art-b64a6531a0ee4c53bb0c2088979ec2e22024-03-26T17:28:02ZengDove Medical PressJournal of Hepatocellular Carcinoma2253-59692024-03-01Volume 1165166391557High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial ChemoembolizationZhang BHuang BYang FYang JKong MWang JXiang YWang KPeng RYang KAn CYan DBaogen Zhang,1,* Biqing Huang,2,* Fan Yang,3,* Jiandong Yang,1 Man Kong,1 Jing Wang,1 Yaoxian Xiang,1 Kangjie Wang,1 Ruchen Peng,4 Kun Yang,4 Chao An,5 Dong Yan1 1Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s Republic of China; 2Department of Interventional Radiology and Vascular Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People’s Republic of China; 3Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, 510630, People’s Republic of China; 4Department of Medical Imaging, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s Republic of China; 5Department of Minimal Invasive Intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Dong Yan, Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, 101149, People’s Republic of China, Tel/Fax +86-10-69543901, Email dongyan@mail.ccmu.edu.cn Chao An, Department of Minimal invasive intervention, Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative, Innovation Center for Cancer Medicine, Guangzhou, 510060, People’s Republic of China, Tel/Fax +86-20-87343272, Email anchao-1983@163.comObjective: To compare the efficacy and safety of hepatic arterial infusion chemotherapy (HAIC) with transarterial chemoembolization (TACE) for the treatment of high-risk hepatocellular carcinoma (hHCC) patients.Methods: Between January 2014 and August 2022, a total of 1765 consecutive patients with hHCC who underwent initial intra-arterial therapies were reviewed and divided into a TACE group (n, 507) and a HAIC group (n, 426). The study used propensity score matching (PSM) to reduce selectivity bias. Overall survival (OS) and progression-free survival (PFS) were compared using Kaplan‒Meier curves with the Log rank test. The objective response rate (ORR), conversion surgery rate (CSR) adverse event (AE) comparison and subgroup analysis were performed between the two groups.Results: After PSM 1:1, 444 patients were divided into two groups. The patients with hHCC who received HAIC had higher median PFS (6.1 vs 3.3 months, P < 0.001) and OS (10.3 vs 8.2 months, P=0.303) than TACE. Higher ORR (24.8% vs 11.7%) and CSR (15.5% vs 8.9%) were found in the HAIC group than in the TACE group (both P < 0.05). The incidence of grade 3/4 AE was 23.9% and 8.1% in the TACE and HAIC groups, respectively. The subgroup analysis suggest that HAIC appeared to particularly benefit patients with tumor diameter of more than 10 centimeters (hazard ratio [HR], 0.6; 95% CI, 0.47– 0.77; p, 0.00) and PVTT Vp4 (HR, 0.56; 95% CI, 0.39– 0.8; P, 0.01) for PFS outperforming TACE.Conclusion: HAIC can provide better disease control for hHCC than cTACE, with a comparable long-term OS and safety.Keywords: hepatocellular carcinoma, transarterial chemoembolization, hepatic artery infusion chemotherapy, high riskhttps://www.dovepress.com/high-risk-hepatocellular-carcinoma-hepatic-arterial-infusion-chemother-peer-reviewed-fulltext-article-JHChepatocellular carcinomatransarterial chemoembolizationhepatic artery infusion chemotherapyhigh risk |
| spellingShingle | Zhang B Huang B Yang F Yang J Kong M Wang J Xiang Y Wang K Peng R Yang K An C Yan D High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization Journal of Hepatocellular Carcinoma hepatocellular carcinoma transarterial chemoembolization hepatic artery infusion chemotherapy high risk |
| title | High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization |
| title_full | High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization |
| title_fullStr | High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization |
| title_full_unstemmed | High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization |
| title_short | High-Risk Hepatocellular Carcinoma: Hepatic Arterial Infusion Chemotherapy versus Transarterial Chemoembolization |
| title_sort | high risk hepatocellular carcinoma hepatic arterial infusion chemotherapy versus transarterial chemoembolization |
| topic | hepatocellular carcinoma transarterial chemoembolization hepatic artery infusion chemotherapy high risk |
| url | https://www.dovepress.com/high-risk-hepatocellular-carcinoma-hepatic-arterial-infusion-chemother-peer-reviewed-fulltext-article-JHC |
| work_keys_str_mv | AT zhangb highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT huangb highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT yangf highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT yangj highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT kongm highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT wangj highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT xiangy highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT wangk highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT pengr highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT yangk highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT anc highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization AT yand highriskhepatocellularcarcinomahepaticarterialinfusionchemotherapyversustransarterialchemoembolization |